Pronosthyc: Prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from the French ENDOCAN-TUTHYREF Network
Dr A. Sagnella , Dr H. Lasolle , Dr Y. Godbert , Dr C. Do Cao , Dr D. Drui , Dr S. Hescot , Dr M. Laramas , Dr C. Sage , Pr J. Wassermann , Dr N. Roudaut , Dr F. Illouz , Pr F. Borson-Chazot , Dr M.B. Abdelouahab , Dr J. Hadoux , Pr I. Borget , Dr C. Buffet , Dr L. Lamartina
{"title":"Pronosthyc: Prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from the French ENDOCAN-TUTHYREF Network","authors":"Dr A. Sagnella , Dr H. Lasolle , Dr Y. Godbert , Dr C. Do Cao , Dr D. Drui , Dr S. Hescot , Dr M. Laramas , Dr C. Sage , Pr J. Wassermann , Dr N. Roudaut , Dr F. Illouz , Pr F. Borson-Chazot , Dr M.B. Abdelouahab , Dr J. Hadoux , Pr I. Borget , Dr C. Buffet , Dr L. Lamartina","doi":"10.1016/j.ando.2024.08.111","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases have a heterogeneous prognosis, spanning from indolent to rapidly progressing disease. Our aim is to assess overall survival (OS) in RAI-R DTC patients and to identify the associated prognostic factors.</div></div><div><h3>Methods</h3><div>A retrospective multicentric (ENDOCAN-TUTHYREF Network) analysis of consecutive cases of distant metastatic RAI-R DTC, diagnosed between 1990 and 2022, was performed. Survival was estimated using the Kaplan-Meier method and prognostic factors were assessed by Cox's model.</div></div><div><h3>Results</h3><div>Our cohort included 899 patients (52.1% females, median age 65 years [20–90] at RAI-R DTC diagnosis). Median follow-up was 4.8 years [0.1–40.1], primary tumour resection in 95.9%. Histotypes were papillary (55.6%), follicular (12.2%), oncocytic (10.6%) and poorly differentiated (21.6%). Metastases diagnosis was synchronous to primary in 39.4%, macroscopic (>1<!--> <!-->cm) in 48.2% and multiple in 83.4% of the cases; 521 (58%) patients were treated with systemic therapies. In 332 (37%) patients, driver mutation status was assessed: 63% BRAFV600E, 29.5% RAS (21% NRAS, 5% HRAS, 3.5% KRAS) mutations and 6% gene fusions (3% RET, 2% NTRK, 1% ALK). After RAI-R DTC diagnosis, median OS was 9.5 years, (5-, 10-year OS rates; 74.8%, 48.1% respectively). Prognostic factors independently associated with worse OS were age ≥55 years (HR<!--> <!-->=<!--> <!-->2.54; 95%CI<!--> <!-->=<!--> <!-->1.84–3.57), multiple metastatic sites (HR<!--> <!-->=<!--> <!-->2.80; 95%CI<!--> <!-->=<!--> <!-->1.80–4.64), macroscopic metastases (HR<!--> <!-->=<!--> <!-->1.98; 95%CI<!--> <!-->=<!--> <!-->1.54–2.55), positive <sup>18</sup>FDG-PET uptake (HR<!--> <!-->=<!--> <!-->2.08; 95%CI<!--> <!-->=<!--> <!-->1.30–3.52), while better OS was associated to primary tumor resection (HR<!--> <!-->=<!--> <!-->0.50; 95%CI<!--> <!-->=<!--> <!-->0.31–0.86), differentiated tumor type (HR<!--> <!-->=<!--> <!-->0.53; 95%CI<!--> <!-->=<!--> <!-->0.41–0.68), metachronous metastatic presentation (HR<!--> <!-->=<!--> <!-->0.64; 95%CI<!--> <!-->=<!--> <!-->0.50–0.82).</div></div><div><h3>Conclusions</h3><div>RAI-R DTC prognosis can be stratified by some simple independent prognostic factors of OS.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"85 5","pages":"Pages 387-388"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales d'endocrinologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003426624002221","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases have a heterogeneous prognosis, spanning from indolent to rapidly progressing disease. Our aim is to assess overall survival (OS) in RAI-R DTC patients and to identify the associated prognostic factors.
Methods
A retrospective multicentric (ENDOCAN-TUTHYREF Network) analysis of consecutive cases of distant metastatic RAI-R DTC, diagnosed between 1990 and 2022, was performed. Survival was estimated using the Kaplan-Meier method and prognostic factors were assessed by Cox's model.
Results
Our cohort included 899 patients (52.1% females, median age 65 years [20–90] at RAI-R DTC diagnosis). Median follow-up was 4.8 years [0.1–40.1], primary tumour resection in 95.9%. Histotypes were papillary (55.6%), follicular (12.2%), oncocytic (10.6%) and poorly differentiated (21.6%). Metastases diagnosis was synchronous to primary in 39.4%, macroscopic (>1 cm) in 48.2% and multiple in 83.4% of the cases; 521 (58%) patients were treated with systemic therapies. In 332 (37%) patients, driver mutation status was assessed: 63% BRAFV600E, 29.5% RAS (21% NRAS, 5% HRAS, 3.5% KRAS) mutations and 6% gene fusions (3% RET, 2% NTRK, 1% ALK). After RAI-R DTC diagnosis, median OS was 9.5 years, (5-, 10-year OS rates; 74.8%, 48.1% respectively). Prognostic factors independently associated with worse OS were age ≥55 years (HR = 2.54; 95%CI = 1.84–3.57), multiple metastatic sites (HR = 2.80; 95%CI = 1.80–4.64), macroscopic metastases (HR = 1.98; 95%CI = 1.54–2.55), positive 18FDG-PET uptake (HR = 2.08; 95%CI = 1.30–3.52), while better OS was associated to primary tumor resection (HR = 0.50; 95%CI = 0.31–0.86), differentiated tumor type (HR = 0.53; 95%CI = 0.41–0.68), metachronous metastatic presentation (HR = 0.64; 95%CI = 0.50–0.82).
Conclusions
RAI-R DTC prognosis can be stratified by some simple independent prognostic factors of OS.
期刊介绍:
The Annales d''Endocrinologie, mouthpiece of the French Society of Endocrinology (SFE), publishes reviews, articles and case reports coming from clinical, therapeutic and fundamental research in endocrinology and metabolic diseases. Every year, it carries a position paper by a work-group of French-language endocrinologists, on an endocrine pathology chosen by the Society''s Scientific Committee. The journal is also the organ of the Society''s annual Congress, publishing a summary of the symposia, presentations and posters. "Les Must de l''Endocrinologie" is a special booklet brought out for the Congress, with summary articles that are always very well received. And finally, we publish the high-level instructional courses delivered during the Henri-Pierre Klotz International Endocrinology Days. The Annales is a window on the world, keeping alert clinicians up to date on what is going on in diagnosis and treatment in all the areas of our specialty.